Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

57.67 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	18,667
Open	57.67
Bid (Size)	58.48 (200)
Ask (Size)	58.75 (100)
Prev. Close	57.67
Today's Range	57.67 - 57.67
52wk Range	42.52 - 62.89
Shares Outstanding	2,222,113,553
Dividend Yield	4.37%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...

Via Finterra

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Performance

YTD	+7.9%	+7.9%
1 Month	-4.9%	-4.9%
3 Month	+6.0%	+6.0%
6 Month	+29.1%	+29.1%
1 Year	+4.5%	+4.5%

More News

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Via MarketMinute

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

Via StockStory

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

Via Finterra

3 Value Stocks Walking a Fine Line

April 02, 2026

Via StockStory

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

Via MarketMinute

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

March 31, 2026

From Bristol Myers Squibb

Via Business Wire

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

March 30, 2026

Via StockStory

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

March 29, 2026

From Bristol Myers Squibb

Via Business Wire

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

March 28, 2026

From Bristol Myers Squibb

Via Business Wire

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

March 26, 2026

Via StockStory

Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

March 25, 2026

Via StockStory

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

March 25, 2026

Via StockStory

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

Via Finterra

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

Via The Motley Fool

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Via MarketMinute

Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗

March 23, 2026

Via The Motley Fool

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

Via MarketMinute

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

March 23, 2026

From Bristol Myers Squibb

Via Business Wire

1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗

March 21, 2026

Via The Motley Fool

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

March 20, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

March 19, 2026

From Bristol Myers Squibb

Via Business Wire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 57.67

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 04/07/26 07:00 PM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 128.15B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 128B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.